74191-85-8

74191-85-8 structure

Name: Doxazosin
Chemical Name: doxazosin
CAS Number: 74191-85-8
Molecular Formula: C₂₃H₂₅N₅O₅
Molecular Weight: 451.48
Catalog: API Circulatory system medication Antihypertensive drug
Create Date: 2018-06-23 12:24:40
Modify Date: 2024-01-09 19:42:42
Doxazosin(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.Target: Adrenergic ReceptorDoxazosin is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms [1]. doxazosin may have a direct inhibitory effect on cholesterol synthesis independent of the LDL receptor. The inhibition of cholesterol synthesis by doxazosin may cause cells to compensate by upregulating the LDL receptor, thereby increasing the importation of lipoprotein cholesterol and reducing LDL cholesterol in the medium [2]. Doxazosin monotherapy was effective in eight of 12 patients (66.7%), and combined therapy with a beta-blocker was effective in 11 of 12 patients (91.7%). The mean pulse rate remained constant throughout therapy. Adverse reactions were minor and transient and occurred in only three patients. Urinary and plasma catecholamine levels tended to decrease or remained unchanged during doxazosin therapy [3].Clinical indications: Hypertension; Prostate hyperplasiaFDA Approved Date: February 22, 2005Toxicity: Symptoms of overdose include hypotension

Name	doxazosin
Synonyms	Doxazosine [French] 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine Doxazosinum Normothen Cardura Doxazosina Doxazosine Cardura-1 Cardura-2 Cardura-4 MFCD00800482 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone

Description	Doxazosin(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.Target: Adrenergic ReceptorDoxazosin is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms [1]. doxazosin may have a direct inhibitory effect on cholesterol synthesis independent of the LDL receptor. The inhibition of cholesterol synthesis by doxazosin may cause cells to compensate by upregulating the LDL receptor, thereby increasing the importation of lipoprotein cholesterol and reducing LDL cholesterol in the medium [2]. Doxazosin monotherapy was effective in eight of 12 patients (66.7%), and combined therapy with a beta-blocker was effective in 11 of 12 patients (91.7%). The mean pulse rate remained constant throughout therapy. Adverse reactions were minor and transient and occurred in only three patients. Urinary and plasma catecholamine levels tended to decrease or remained unchanged during doxazosin therapy [3].Clinical indications: Hypertension; Prostate hyperplasiaFDA Approved Date: February 22, 2005Toxicity: Symptoms of overdose include hypotension
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Natural Products >> Alkaloid Research Areas >> Cardiovascular Disease
References	[1]. Sun, J.A., et al., Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro. Acta Pharmacol Sin, 2013. 34(12): p. 1568-74. [2]. D'Eletto, R.D. and N.B. Javitt, Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol, 1989. 13 Suppl 2: p. S1-4; discussion S4. [3]. Miura, Y. and K. Yoshinaga, Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma. Am Heart J, 1988. 116(6 Pt 2): p. 1785-9.

Density	1.371 g/cm3
Boiling Point	718ºC at 760 mmHg
Melting Point	289-290°C
Molecular Formula	C₂₃H₂₅N₅O₅
Molecular Weight	451.48
Flash Point	388ºC
PSA	175.02000
LogP	2.88670
Storage condition	-20℃

Hazard Codes	T,Xi
Risk Phrases	R23/24/25:Toxic by inhalation, in contact with skin and if swallowed . R34:Causes burns. R40:Limited evidence of a carcinogenic effect. R43:May cause sensitization by skin contact. R36/37/38:Irritating to eyes, respiratory system and skin . R38:Irritating
Safety Phrases	S36/37-S37/39-S26-S36
RIDADR	UN 1198 3/PG 3
WGK Germany	2
RTECS	LP8925000